What is Rallybio?
Rallybio operates as a specialized biotechnology entity dedicated to the identification and acceleration of life-transforming therapies. The company focuses on severe and rare disorders, with a research and development footprint spanning hematology, immuno-inflammation, and metabolism. By leveraging a sophisticated approach to drug discovery, Rallybio aims to bridge the gap between scientific innovation and patient access for conditions that have historically lacked effective treatment options. Its market position is defined by a commitment to high-impact therapeutic development, supported by a robust network of institutional investors who prioritize long-term value creation in the life sciences sector.
How much funding has Rallybio raised?
Rallybio has raised a total of $355.8M across 4 funding rounds:
Series A
$37M
Share Placement
$93.2M
Series B
$145M
Share Placement
$80.6M
Series A (2018): $37M, investors not publicly disclosed
Share Placement (2020): $93.2M, investors not publicly disclosed
Series B (2020): $145M supported by VIKING GLOBAL INVESTORS L.P., Fairview Capital Partners Inc, Mitsui & Co., F-Prime Capital, PIVOTAL BIOVENTURE PARTNERS LLC, Tekla Life Sciences Investors, The Rise Fund, and Solasta Ventures
Share Placement (2021): $80.6M, investors not publicly disclosed
Key Investors in Rallybio
Mitsui & Co.
Mitsui & Co. is a global trading and investment company that leverages its extensive cross-industry expertise and geographic reach to support healthcare solutions and sustainable business growth.
F-Prime Capital
F-Prime Capital is a venture firm comprised of scientists, engineers, and investors dedicated to funding high-potential healthcare and technology companies.
The Rise Fund
The Rise Fund is an impact investing platform that focuses on mission-driven, growth-stage companies aligned with global sustainability and healthcare improvement goals.
What's next for Rallybio?
With the recent capital infusion, Rallybio is well-positioned to accelerate its clinical development programs. The strategic focus will likely remain on advancing its lead candidates through regulatory milestones while maintaining operational agility. As the company matures, the emphasis will shift toward scaling its research infrastructure and potentially expanding its therapeutic reach into new, underserved patient populations. The continued support from global investment partners suggests a strong outlook for the firm's ability to navigate the complexities of the biotech regulatory environment and deliver sustainable clinical outcomes.
See full Rallybio company page
